1
|
E1 Clinical Safety for Drugs used in Long-Term Treatment/长期使用的药物的临床安全性
|
|
E1: The extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-term Treatment of Non-life-threatening Conditions
|
E1:人群暴露程度:评估非危及生命性疾病长期治疗药物的临床安全性
|
阶段5
|
1994.10.27
|
有
|
2
|
E2A - E2F Pharmacovigilance/药物警戒性
|
|
E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
|
E2A: 临床安全性数据管理:快速报告的定义和标准
|
阶段5
|
1994.10.27
|
有
|
E2B(R3):Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) E2B(R3) Data Elements and Message Specification
|
E2B(R3):个例安全报告(ICSR)电子传输执行指导原则 E2B(R3)数据元素和信息规范元素 (中文版:征求意见稿)
|
阶段5
|
2016.11.10
|
有
|
E2B(R3) QA document_v2_1
|
E2B(R3) 问答文件(中文版:征求意见稿)
|
阶段5
|
2017.6.1
|
有
|
E2C(R2): Periodic Benefit-Risk Evaluation Report
|
E2C(R2): 定期获益—风险评估报告
|
阶段5
|
2012.12.17
|
有
|
E2C(R2) Implementation Working Group Questions & Answers
|
E2C(R2)实施工作组 问答部分
|
阶段5
|
2014.3.31
|
有
|
E2D: Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
|
E2D: 上市后安全性数据的管理:快速报告的定义和标准(中文版:征求意见稿)
|
阶段5
|
2003.11.12
|
有
|
E2E: Pharmacovigilance Planning
|
E2E:药物警戒计划
|
阶段5
|
2004.11.18
|
有
|
E2F:Example DSUR – Phase III Investigational Drug
|
E2F:研发期间安全性更新报告示例
|
|
2010.10.05
|
有
|
E2F: Development Safety Update Report
|
E2F:研发期间安全性更新报告
|
阶段5
|
2010.8.17
|
有
|
3
|
E3 Clinical Study Reports/临床研究报告
|
|
E3: Structure and Content of Clinical Study Reports
|
E3:临床研究报告的结构与内容
|
阶段5
|
1995.11.30
|
有
|
E3 Questions & Answers (R1) : Structure and Content of Clinical Study Reports
|
E3:临床研究报告的结构和内容问与答(R1)
|
阶段5
|
2012.7.6
|
有
|
4
|
E4 Dose-Response Studies/剂量反应研究
|
|
E4: Dose-Response Information to Support Drug Registration
|
E4:药品注册所需的量效关系信息
|
阶段5
|
1994.3.10
|
有
|
5
|
E5 Ethnic Factors/种族因素
|
|
E5(R1): Ethnic Factors in the Acceptability of Foreign Clinical Data
|
E5(R1):接受国外临床试验数据的种族因素
|
阶段5
|
1998.2.5
|
有
|
E5 Implementation Working Group Questions & Answers (R1)
|
E5:接受国外临床试验数据的种族因素问答(R1)
|
阶段5
|
2006.6.2
|
有
|
6
|
E6 GCP/药物临床试验管理规范
|
|
E6(R1): Guideline for Good Clinical Practice
|
E6(R1):药物临床试验管理规范指导原则
|
阶段5
|
1996.6.10
|
有
|
E6(R2):Integrated Addendum to Good Clinical Practice (GCP)
|
E6(R2):药物临床试验管理规范综合附录
|
阶段5
|
2016.11.9
|
|
7
|
E7 Clinical Trials in Geriatric Population/老人中开展的临床试验
|
|
E7: Studies in Support of Special Populations: Geriatrics
|
E7:特殊人群的研究:老年医学
|
阶段5
|
1993.6.24
|
有
|
E7 Questions & Answers
|
E7 特殊人群的研究:老年医学问答
|
阶段5
|
2010.7.6
|
有
|
8
|
E8 General Considerations for Clinical Trials/临床试验的一般性考虑
|
|
E8(R1): General Considerations for Clinical Trials
|
E8(R1):临床试验的一般考虑
|
阶段5
|
2021.10.06
|
有
|
9
|
E9 Statistical Principles for Clinical Trials/临床试验的统计原则
|
|
E9: Statistical Principles for Clinical Trials
|
E9:临床试验的统计学原则
|
阶段5
|
1998.2.5
|
有
|
E9(R1): Addendum on E stimands and Sensitivity Analysis in Clinical Trials
|
E9(R1):临床试验中的估计目标与敏感性分析(E9指导原则增补文件)
|
阶段5
|
2019.11.20
|
有
|
10
|
E10 Choice of Control Group in Clinical Trials/试验中对照组的选择
|
|
E10: Choice of Control Group and Related Issues in Clinical Trials
|
E10:临床试验中对照组的选择和相关问题
|
阶段5
|
2000.7.20
|
有
|
11
|
E11 Clinical Trials in Pediatric Population/儿童人群临床研究
|
|
E11(R1): Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population
|
E11(R1):用于儿科人群的医学产品的药物临床研究
|
阶段5
|
2017.8.18
|
有
|
12
|
E12 Clinical Evaluation by Therapeutic Category/根据治疗类别进行临床评价
|
|
E12A: Principles for Clinical Evaluation of New Antihypertensive Drugs
|
E12A:抗高血压新药临床评价原则
|
阶段5
|
2000.3.2
|
有
|
13
|
E14 Clinical Evaluation of QT/QT临床评价
|
|
E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs
|
E14:非抗心律失常药物QT/QTc间期延长及致心律失常潜力的临床评价
|
阶段5
|
2005.5.12
|
有
|
E14 Implementation Working Group Questions & Answers (R3)
|
E14 实施工作组 问答部分(R3)
|
阶段5
|
2015.12.10
|
有
|
E14/S7B: Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers
|
E14/S7B: QT/QTc 间期延长及潜在致心律失常作用的临床和非临床评价问答
|
阶段5
|
2022.02.21
|
有
|
14
|
E15 Definitions in Pharmacogenetics/Pharmacogenomics/药物基因组学以及遗传药理学相关定义
|
|
E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories
|
E15:基因组生物标志物、药物基因组学、遗传药理学、基因组数据和样本编码分类的定义
|
阶段5
|
2007.11.1
|
有
|
15
|
E16 Qualification of Genomic Biomarkers/基因组生物标志物的合格条件
|
|
E16: Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions
|
E16:药物或生物技术产品开发相关的生物标志物:资格认定申请的背景资料、结构和格式
|
阶段5
|
2010.8.20
|
有
|
16
|
E17 Multi-Regional Clinical Trials/多地区临床试验
|
|
E17: General principle on planning and Designing Multi-Regional Clinical Trials
|
E17:多区域临床试验计划与设计的一般原则
|
阶段5
|
2019.11.12
|
有
|
17
|
E18 Genomic Sampling/基因组取样
|
|
E18: Genomic Sampling and Management of Genomic Data
|
E18:基因组采样和基因组数据管理指导原则(中文翻译公开征求意见稿)
|
阶段5
|
2015.12.10
|
有
|
18
|
E19:A Selective Approach To Safety Data Collection In Specific Late-Stage Pre-approval Or Post-Approval Clinical Trials/在特定的上市前后期或上市后临床试验中选择性收集安全性数据
|
|
E19:A Selective Approach To Safety Data Collection In Specific Late-Stage Pre-approval Or Post-Approval Clinical Trials
|
E19:在特定的上市前后期或上市后临床试验中选择性收集安全性数据
|
阶段5
|
2022.09.27
|
有
|